Indolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in rats.
Nicolas G. Glynos, Lily Carter, Soo Jung Lee, Youngsoo Kim, Robert T. Kennedy, George A. Mashour, Michael M Wang, Jimo Borjigin
Scientific Reports January 6, 2023 DOI: 10.1038/s41598-023-27538-y (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study using knockout rat model Peer reviewed |
|---|---|
| Population | Rats (wild type and INMT-knockout) |
| Keywords | Psychedelics Biochemistry Enzymes Brain chemistry |
| Citations | 17 |
| Key findings | INMT is not necessary for DMT biosynthesis in rats, suggesting an alternative enzymatic pathway. |
Abstract
Indolethylamine N-methyltransferase (INMT) is a transmethylation enzyme that utilizes the methyl donor S-adenosyl-L-methionine to transfer methyl groups to amino groups of small molecule acceptor compounds. INMT is best known for its role in the biosynthesis of N,N-Dimethyltryptamine (DMT), a psychedelic compound found in mammalian brain and other tissues. In mammals, biosynthesis of DMT is thought to occur via the double methylation of tryptamine, where INMT first catalyzes the biosynthesis of N-methyltryptamine (NMT) and then DMT. However, it is unknown whether INMT is necessary for the biosynthesis of endogenous DMT. To test this, we generated a novel INMT-knockout rat model and studied tryptamine methylation using radiometric enzyme assays, thin-layer chromatography, and ultra-high-performance liquid chromatography tandem mass spectrometry. We also studied tryptamine methylation in recombinant rat, rabbit, and human INMT. We report that brain and lung tissues from both wild type and INMT-knockout rats show equal levels of tryptamine-dependent activity, but that the enzymatic products are neither NMT nor DMT. In addition, rat INMT was not sufficient for NMT or DMT biosynthesis. These results suggest an alternative enzymatic pathway for DMT biosynthesis in rats. This work motivates the investigation of novel pathways for endogenous DMT biosynthesis in mammals.
Citations in the library
Cited by 11
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025
- Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cellular and Molecular Life Sciences September 10, 2024
- The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity. Psychopharmacology April 11, 2025
- Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics. Frontiers in Psychiatry November 6, 2024
- Exploring the biocatalysis of psilocybin and other tryptamines: Enzymatic pathways, synthetic strategies, and industrial implications Biotechnology Progress October 4, 2024
and 6 more in the library
Cites 7
- Dose-Response Study of N,N-Dimethyltryptamine in Humans Archives of General Psychiatry February 1, 1994
- Enzymatic Formation of Psychotomimetic Metabolites from Normally Occurring Compounds Science August 4, 1961
- N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function Frontiers in Neuroscience August 6, 2018
- A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010. Drug Testing and Analysis 2012
- Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain. Scientific Reports June 27, 2019
and 2 more in the library